This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

50/100

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Disease mechanisms

Topic: Amyloid, tau and blood-test diagnosis

Background People with Alzheimer's disease (AD) experience, in addition to the progressive loss of cognitive functions, a decline in functional performance such as mobility impairment and disability in activities of daily living (ADL). Functional decline in dementia is mainly linked to the progressive brain pathology. Peripheral biomechanical changes by advanced glycation end-products (AGEs) have been suggested but have yet to be thoroughly studied. Methods A multi-center, longitudinal, one-year follow-up cohort study was conducted in 144 people with early stage AD or mixed Alzheimer's/Vascular dementia. Linear mixed model analyses was used to study associations between AGE-levels (AGE reader) and mobility (Timed Up and Go), and ADL (Groningen Activity Restriction Scale and Barthel index), respectively. Results A significant association between AGE levels and mobility (β = 3.57, 95%CI: 1.43-5.73) was revealed; however, no significant association between AGE levels and ADL was found. Over a one-year time span, mean AGE levels significantly increased, and mobility and ADL performance decreased. Change in AGE levels was not significantly correlated with change in mobility. Conclusions This study indicates that high AGE levels could be a contributing factor to impaired mobility but lacks evidence for an association with ADL decline in people with early stage AD or mixed dementia. Future research is necessary on the reduction of functional decline in dementia regarding the effectiveness of interventions such as physical activity programs and dietary advice possibly in combination with pharmacologic strategies targeting AGE accumulation.

Key findings

Results A significant association between AGE levels and mobility (β = 3.57, 95%CI: 1.43-5.73) was revealed; however, no significant association between AGE levels and ADL was found.
Over a one-year time span, mean AGE levels significantly increased, and mobility and ADL performance decreased.
Change in AGE levels was not significantly correlated with change in mobility.
Conclusions This study indicates that high AGE levels could be a contributing factor to impaired mobility but lacks evidence for an association with ADL decline in people with early stage AD or mixed dementia.

Why it matters

Following 144 people with early Alzheimer's or mixed dementia for a year, researchers found that higher levels of advanced glycation end products (AGEs) were associated with poorer mobility, but not with daily-living abilities. AGE levels rose and function declined over the year, though the change in AGEs did not track the change in mobility. The authors suggest AGEs may contribute to mobility problems and call for research on exercise, diet or drugs targeting AGE build-up.

Study details

Study designcohort study
Participants144
Evidence strengthModerate

How this study scored 50/100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (International psychogeriatrics)
Journal's citation record	2 / 4	International Psychogeriatrics: journal h-index 161 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	2 / 5	2017 — within 10 year(s) of the newest study here
Sample size	2 / 4	144 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	3 / 7	Cited 18 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	1.6 citations a year over 11 year(s) since 2017
Impact for its field and year	2 / 6	Cited 1.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Hans J. S. M. Hobbelen: h-index 26 (OpenAlex, whole career)
Institution's track record	1 / 3	University of Groningen: institution h-index 1,383 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 28539135)
Free to read	0 / 2	Behind a paywall — scores zero
Total	50 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Drenth, H., Zuidema, S. U., Krijnen, W. P., Bautmans, I., van der Schans, C., & Hobbelen, H. (2017). Association between advanced glycation end-products and functional performance in Alzheimer's disease and mixed dementia. International psychogeriatrics. https://doi.org/10.1017/s1041610217000886

Vancouver

Drenth H, Zuidema SU, Krijnen WP, Bautmans I, van der Schans C, Hobbelen H. Association between advanced glycation end-products and functional performance in Alzheimer's disease and mixed dementia. International psychogeriatrics. 2017. doi:10.1017/s1041610217000886. PMID: 28539135.

BibTeX

@article{drenth2017-28539135,
  author  = {Drenth, H. and Zuidema, S. U. and Krijnen, W. P. and Bautmans, I. and van der Schans, C. and Hobbelen, H.},
  title   = {{Association between advanced glycation end-products and functional performance in Alzheimer's disease and mixed dementia}},
  journal = {International psychogeriatrics},
  year    = {2017},
  doi     = {10.1017/s1041610217000886},
  pmid    = {28539135},
  url     = {https://doi.org/10.1017/s1041610217000886}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Disease mechanisms

Also tagged “amyloid-beta”

1,339 studies in the library carry the topic tag “amyloid-beta”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →